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Abstract
Introduction: In phase-3 clinical trials, the interleukin (IL-1) blocker, rilonacept (IL-1 Trap), demonstrated efficacy for
gout flare prevention during initiation of urate-lowering therapy. This trial evaluated rilonacept added to a
standard-of-care, indomethacin, for treatment of acute gout flares.
Methods: Adults, aged 18-70 years, with gout presenting within 48 hours of flare onset and having at least
moderate pain as well as swelling and tenderness in the index joint were randomized to subcutaneous (SC)
rilonacept 320 mg at baseline plus oral indomethacin 50 mg TID for 3 days followed by 25 mg TID for up to 9
days (n = 74); SC placebo at baseline plus oral indomethacin as above (n = 76); or SC rilonacept 320 mg at
baseline plus oral placebo (n = 75). The primary efficacy endpoint was change in pain in the index joint (patient-
reported using a Likert scale (0 = none; 4 = extreme)) from baseline to the average of values at 24, 48 and 72
hours (composite time point) for rilonacept plus indomethacin versus indomethacin alone. Comparison of
rilonacept monotherapy with indomethacin monotherapy was dependent on demonstration of significance for the
primary endpoint. Safety evaluation included clinical laboratory and adverse event (AE) assessments.
Results: Patient characteristics were comparable among the groups; the population was predominantly male
(94.1%), white (75.7%), with mean ± SD age of 50.3 ± 10.6 years. All treatment groups reported within-group pain
reductions from baseline (P < 0.0001). Although primary endpoint pain reduction was greater with rilonacept plus
indomethacin (-1.55 ± 0.92) relative to indomethacin alone (-1.40 ± 0.96), the difference was not statistically
significant (P = 0.33), so formal comparison between monotherapy groups was not performed. Pain reduction over
the 72-hour period with rilonacept alone (-0.69 ± 0.97) was less than that in the other groups, but pain reduction
was similar among groups at 72 hours. Treatment with rilonacept was well-tolerated with no reported serious AEs
related to rilonacept. Across all groups, the most frequent AEs were headache and dizziness.
Conclusions: Although generally well-tolerated, rilonacept in combination with indomethacin and rilonacept alone
did not provide additional pain relief over 72 hours relative to indomethacin alone in patients with acute gout
flare.
Trial registration: ClinicalTrials.gov registration number NCT00855920.
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Introduction
A cardinal clinical feature of gout is recurrent acute
inflammatory flares (acute gout flares) that result in
debilitating joint pain and swelling. Gouty arthritis is
mediated by monosodium urate monohydrate crystal
deposition in and around the joint space due to hyperuri-
cemia. Acute gout flares can be precipitated by a variety
of factors including joint trauma, and putative remodel-
ing of articular crystal deposits due to changes in serum
urate concentrations, such as during the early months of
initiation of uric acid-lowering therapy (ULT) [1,2].
The incidence and prevalence of gout are increasing,
partly as a consequence of increased prevalence of comor-
bidities such as metabolic syndrome, type II diabetes, obe-
sity, hypertension, and chronic kidney disease [3,4]. Gout
is associated with a substantial economic burden due to
high health care resource utilization and reduced work
productivity [5-7], especially among patients who are
refractory to conventional gout management strategies
[8,9].
Because of their anti-inflammatory and analgesic char-
acteristics, non-steroidal anti-inflammatory drugs
(NSAIDs) are often used as first-line therapy for the
treatment of acute gout flares [10,11]. Colchicine and sys-
temic and locally injected corticosteroids are also appro-
priate options in many patients [10-12], with the
corticosteroid prednisolone in particular showing equiva-
lent efficacy to the NSAID naproxen [13]. However, col-
chicine is associated with risks of toxicity especially
related to renal impairment and drug-drug interactions
[14], and NSAIDs are also associated with clinically
recognized risks of toxicities, especially related to their
gastrointestinal and cardiovascular effects [15,16]. In a
recent study, more than 90% of gout patients had a rela-
tive or absolute contraindication to NSAIDs, and up to
66% of patients had a contraindication to colchicine or a
condition warranting colchicine dose reduction [17]. The
presence of comorbid conditions in these patients
included hypertension (88.7%), coronary artery disease
(37.4%), chronic kidney disease (47.1%), and gastroeso-
phageal disease (> 20%), with 65% of patients having mul-
tiple comorbidities [17]. Such risks increase among
individuals with comorbidities and in those taking multi-
ple medications, circumstances that are common in older
adults [18,19]. Moreover, the intense pain of gout attacks
is reduced with NSAID, colchicine, or corticosteroid
therapy by only approximately 50% in 1 to 3 days in most
clinical trials [12,13,20,21]. Consequently, there is a need
for new approaches that provide increased efficacy and/
or tolerability in the treatment of acute gouty arthritis.
IL-1b is a major mediator of gouty inflammation and
pain [22], and is now being increasingly evaluated for its
role in acute and chronic gout. Of particular relevance
is the observation that monosodium urate (MSU) crys-
tals induce activation of the NLRP3 inflammasome, a
protein complex expressed in macrophages and certain
other cell types, which promotes caspase-1-driven
release of mature IL-1b, with subsequent induction of
numerous downstream inflammatory mediators that
contribute to the clinical presentation of the signs and
symptoms of gouty arthritis [23]. Neutrophils and mast
cells also express proteases such as elastase and chy-
mase, respectively, that activate pro-IL-1b [24]. Data
from case reports and early-phase clinical trials of the
IL-1 inhibitors anakinra and canakinumab confirmed
the role of IL-1 inhibition as a treatment option for
acute gout [25-30]. In particular, studies of the IL-1b-
specific monoclonal antibody canakinumab for the treat-
ment of an acute gout flare provided evidence of efficacy
relative to a single intramuscular (IM) low dose of
triamcinolone acetonide 40 mg [30,31].
Rilonacept is a fully-human, recombinant, soluble
decoy receptor protein engineered from human IL-1
receptors and IgG1Fc that binds IL-1a and IL-1b, thus
preventing their activation of cell surface receptors [32].
Since rilonacept was generated using so-called Trap
Technology, it is also known as the IL-1 Trap [32]. The
half-life of rilonacept is approximately 1 week [33].
Recent clinical trials of rilonacept in gout have demon-
strated significant and marked efficacy vs placebo for
prevention of acute gout flare over 4 months, among
patients initiating ULT with allopurinol [34,35]. We
therefore tested in the current study the hypothesis that
a single subcutaneous (SC) administration of rilonacept,
along with an oral NSAID, during the first 48 hours of
an acute gout flare can reduce the pain of the gout
attack compared to NSAID alone. Specifically, in this
superiority study, we evaluated the efficacy and safety of
SC rilonacept as add-on therapy to a standard-of-care
NSAID regimen of oral indomethacin, rilonacept mono-
therapy, and indomethacin monotherapy, for the reduc-
tion of pain in patients experiencing an acute gout flare.
Materials and methods
Study design and patient population
This phase 3, randomized, double blind, double-dummy,
active- and placebo-controlled study was conducted at
60 study centers in North America. The study was per-
formed in accordance with the revised Declaration of
Helsinki, approval was obtained from the independent
ethics committee (Copernicus Group IRB, One Triangle
Drive, Suite 100, Research Triangle Park NC 27709),
and all patients provided written informed consent.
The study was open to male and female patients 18 to
70 years of age having a diagnosis of primary gout based
on the American Rheumatism Association (1977 ARA
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preliminary criteria) for the classification of acute arthritis
of primary gout [36]. Eligible patients must also have pre-
viously demonstrated symptomatic relief with NSAIDs for
treatment of gout flare. Exclusion criteria included, but
were not limited to treatment with short-acting NSAIDs
within 48 hours of randomization, or other NSAIDs based
on duration of action; use of systemic glucocorticoids
within 4 weeks of randomization; use of colchicine at a
dose exceeding 0.6 mg twice daily within 7 days of rando-
mization; a history of NSAID intolerance or absolute con-
traindication; active or recurrent infections, and estimated
creatinine clearance < 60 mL/minute using the Cockcroft-
Gault method [37]. Since NSAID use was required in this
study, a history of bleeding disorders, gastrointestinal
bleeding or perforation, as well as poorly controlled hyper-
tension and other cardiovascular risk factors were reasons
for exclusion.
Eligible patients remained in screening and were subse-
quently randomized to treatment when they presented
with an acute flare within 48 hours of pain onset and met
the following additional criteria: pain in the gouty index
joint of at least moderate severity using a 5-point Likert
scale (1 = none, 2 = mild, 3 = moderate, 4 = severe, 5 =
extreme), a score of at least 1 on a scale of 0 to 3 for
assessments of swelling and tenderness at the gouty
index joint, and presentation of acute gout flare in three
joints or fewer. The index joint was defined as the joint
that was most painful at the time of randomization.
Randomization and dosing
Patients were randomly allocated 1:1:1 to treatment with
either SC placebo at baseline plus oral indomethacin 50
mg three times daily for 3 days (and then 25 mg three
times daily for up to 9 days); SC rilonacept 320 mg at
baseline plus oral indomethacin as above; or SC rilonacept
320 mg at baseline plus oral placebo three times daily for
3 days and then oral placebo three times daily for up to
9 days. Randomization was stratified by baseline pain
score (moderate, or severe or greater) and country.
On-site study visits occurred at baseline (day 1), days 4
and 8, and at a safety follow up on day 31.
Endpoints
Patient self-assessment of pain and other gout symptoms
were recorded using an electronic diary at baseline, 4, 8,
12, and 24 hours, and then daily until the flare ended. Pain
was assessed using the 5-point Likert scale and an
11-point numerical rating scale (NRS; 0 = no pain to 10 =
extreme pain).
Based on index joint pain, patients were eligible for res-
cue medication at two time points. At 24 hours, patients
with extreme pain or severe pain that had not decreased
from baseline were eligible for rescue medication with
blinded indomethacin 50 mg three times daily for 1 day
(group not receiving indomethacin, that is, rilonacept
only group) or blinded placebo rescue in the other two
treatment groups receiving indomethacin. At 48 hours
patients with either a) extreme pain alone or b) moderate
or severe pain and pain reduction from baseline less than
20% were eligible to receive blinded rescue with indo-
methacin in the rilonacept-only group (50 mg three
times daily for 1 day, followed by 25 mg three times daily
for up to 9 days), or with placebo in the two groups
receiving indomethacin; the duration of rescue was deter-
mined by the investigator. Patients receiving rescue med-
ication were not required to be withdrawn. For all
groups, efficacy data were set to missing after initiation
of rescue medication. The last observation carried for-
ward (LOCF) method was used to impute data after res-
cue medication for the analysis of covariance (ANCOVA)
model, used for the primary analysis.
The primary efficacy endpoint was the change in
patient-reported pain (Likert scale) in the index joint
from baseline to the average of the patient-reported pain
values at 24 (day 2), 48 (day 3) and 72 hours (day 4)
(composite time point). Secondary efficacy endpoints
included the change from baseline in patient-reported
pain in the index joint at days 2, 3, and 4. Additional
exploratory analyses included proportion of patients
requiring rescue medication. Blood samples were
obtained for analysis of high sensitivity C-reactive protein
(hs-CRP), an established marker of inflammation, at
baseline and at study visits on days 4, 8, and 31. Safety
and tolerability were evaluated based on the incidence of
adverse events (AEs) up to and including the safety fol-
low up visit, and the occurrence of clinically significant
laboratory findings determined by the investigator.
Statistical analysis
For this superiority study, a pre-specified step-down
sequential testing procedure was used for the primary effi-
cacy endpoint that compared rilonacept alone vs indo-
methacin alone only if the comparison of rilonacept +
indomethacin vs indomethacin alone was statistically
significant (P < 0.05). ANCOVA was used for the sequen-
tial testing of endpoints with treatment and baseline pain
score strata (moderate, or severe or greater) and country as
fixed effects. The LOCF was used for imputation of miss-
ing data, and pain scores obtained after rescue medication
were considered missing for the primary efficacy analysis.
A sample size of 75 patients per group was calculated to
provide at least 90% power for pairwise comparisons
based on the following assumptions: a 1-point improve-
ment from baseline for the control group; a 2-point
change in the comparator group, and a constant SD of
0.85, for 2-sided alpha level of 0.05 for the comparisons.
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All analyses were performed using SAS Version 9
(SAS Institute, Cary, NC, USA). The full analysis set
included all randomized patients who received any study
medication and had at least one post-baseline assess-
ment, and the safety set included all patients who
received any study medication.
Results
Figure 1 shows the distribution and flow through the
study of the 225 patients who were randomized to treat-
ment. The demographic and clinical characteristics were
generally similar among the treatment groups (Table 1)
with a population that was predominantly male (94.1%)
and white (75.7%), a mean (SD) age of 50.3 (10.6) years,
and a body mass index of 33.1 (6.9), indicating obesity.
Mean serum urate was 8.27 mg/dL, 15.8% of patients had
visible tophi on examination, and 40.1% of patients had a
history of ULT use. Prior use of analgesic medications
(paracetamol or acetylsalicylic acid) as reported at base-
line was low (8.2%).
All treatment groups were observed to have significant
reductions in pain from baseline when averaged at 24, 48
and 72 hours (P < 0.0001) and assessed using the Likert
scale. However, the mean reduction in pain with rilona-
cept plus indomethacin, 1.55 points, was not statistically
significantly greater than the mean reduction in pain
with indomethacin alone, which was 1.40 points (least
squares mean difference -0.14, 95% CI -0.44, 0.15, P =
0.333) (Figure 2A). Since the difference was not signifi-
cant, formal comparison between pain reduction in the
rilonacept monotherapy group, which was 0.69 points,
and the indomethacin monotherapy group, which was
1.40 points, was not required. However, a separate ad
hoc analysis for this comparison showed that the differ-
ence between indomethacin monotherapy and rilonacept
monotherapy significantly favored indomethacin (P <
0.0001). Similar results were observed with the NRS; sig-
nificant reductions from baseline were observed in each
of the treatment groups (P < 0.0001), with pain reduc-
tions of 3.87 in the rilonacept plus indomethacin group,
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Figure 1 Flow of patients through the study. SC, subcutaneous.
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4.33 in the indomethacin monotherapy group, and 1.81
in the rilonacept monotherapy group (Figure 2B). While
the NRS change with rilonacept plus indomethacin was
similar to that of indomethacin alone (P = 0.2533), the ad
hoc analysis significantly favored indomethacin mono-
therapy relative to rilonacept monotherapy (P < 0.0001).
For the secondary endpoints of mean change in pain at
24, 48, and 72 hours (Figure 3), the trends in pain reduc-
tion among the three treatment groups were similar
when pain was assessed using the Likert scale and the
NRS; no significant differences were observed with rilo-
nacept plus indomethacin relative to indomethacin
monotherapy, but indomethacin monotherapy was signif-
icantly superior to rilonacept monotherapy at all time
points (P < 0.05).
The proportion of patients who reported having taken
rescue medication at > 24 to 48 hours in the rilonacept
plus indomethacin group (3.0%) was similar to the indo-
methacin monotherapy group (4.3%).
All treatment groups were characterized by a general
reduction from baseline in hs-CRP from initiation of
treatment to the safety follow up at day 31 (Figure 4). At
day 4, these reductions were significantly greater with
rilonacept plus indomethacin (P < 0.0001) and rilonacept
monotherapy (P = 0.0142) relative to indomethacin
monotherapy.
Overall, the incidence of AEs was higher in the groups
treated with rilonacept relative to indomethacin alone
(Table 2); AEs were generally of mild to moderate severity.
There were three patients with five serious AEs reported
(hypertensive cardiomyopathy, myocardial infarction,
ulcerative colitis, tubulointerstitial nephritis, and pyo-
derma gangrenosum), all in the rilonacept plus indo-
methacin group, which were not considered by the
investigator to be related to treatment with rilonacept.
One death was due to hypertensive cardiomyopathy that
was not considered by the investigator to be related to
treatment with rilonacept. Similar proportions of patients
in each treatment group withdrew due to AEs, and the
most frequently reported AEs were headache and dizzi-
ness, each of which occurred with a similar incidence
across the treatment groups (Table 2).
Discussion
Whereas rilonacept has previously demonstrated efficacy
in prevention of gout flare during initiation of ULT with
allopurinol [34,35], the current study showed that adding
rilonacept to indomethacin for the treatment of acute
Table 1 Baseline demographic and clinical characteristics
Variable SC placebo + oral
indomethacin
(n = 75)
SC rilonacept + oral
indomethacin
(n = 74)
SC rilonacept + oral
placebo
(n = 73)
Age, years, mean (SD) 51.3 (10.9) 48.6 (10.0) 51.0 (10.8)
Gender, n (%)
Male 71 (94.7) 71 (95.9) 67 (91.8)
Female 4 (5.3) 3 (4.1) 6 (8.2)
Race, n (%)
White 54 (72.0) 54 (73.0) 60 (82.2)
Black or African American 15 (20.0) 15 (20.3) 11 (15.1)
Asian 5 (6.7) 2 (2.7) 2 (2.7)
Other 1 (1.3) 3 (4.1) 0
BMI, kg/m2, mean (SD) 32.1 (6.3) 33.5 (7.5) 33.7 (6.7)
Pain severity, mean (SD)
Likert scale (0 to 4) 2.6 (0.7) 2.7 (0.7) 2.6 (0.7)
Numerical rating scale (0 to 10) 6.8 (2.2) 6.8 (2.0) 6.5 (2.3)
Duration of disease, years, mean (SD) 8.8 (6.7) 11.0 (7.9) 10.2 (9.9)
Prior number of gout flares per year, mean
(SD)
4.8 (5.19) 5.5 (5.26) 5.2 (4.76)
Duration of a typical gout flare, days, mean
(SD)
5.8 (3.6) 7.1 (4.2) 6.8 (7.3)
Tophi present, n (%) 10 (13.3) 12 (16.2) 13 (17.8)
Serum uric acid, mg/dL, mean (SD) 7.9 (1.9) 8.2 (2.1) 8.3 (1.7)
Prior medication use, n (%)
Urate-lowering therapy 28 (37.3) 34 (45.9) 27 (37.0)
Analgesics (paracetamol or acetylsalicylic
acid)
2 (2.7) 9 (12.2) 7 (9.6)
BMI, body mass index.
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gout flares did not result in significantly greater pain relief
compared to indomethacin alone over the 72-hour period
following initiation of treatment. Importantly, the similarity
of the magnitude of the pain reduction observed with indo-
methacin in this study to that reported in previous studies
[38,39] buttresses the current data. Although rilonacept
monotherapy was not formally compared with the other
treatment groups, the reduction in pain at 24 and 48 hours
with this regimen was clearly less than that achieved with
the other treatment regimens, and was demonstrated to
be significantly inferior to indomethacin monotherapy in













































































































Figure 2 Change in pain from baseline. Data are mean change in pain of the index joint from baseline to pain averaged for the 24-, 48-, and
72-hour assessments for (A) the primary endpoint using a Likert scale (0 = no pain to 4 = extreme pain), and (B) using a numerical rating scale
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Figure 3 Mean change in pain of the index joint from baseline at 24, 48, and 72 hours. (A) Likert scale (0 = no pain to 4 = extreme pain).
(B) Numerical rating scale (0 = no pain to 10 = extreme pain). SC, subcutaneous.
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72 hours for the three groups was similar. This may reflect
a delayed effect of rilonacept or could simply reflect the
self-limiting natural course of an acute gout flare [40].
Several factors may account for the observed results. In
this study, rilonacept was administered within 48 hours of
onset of an acute gout flare in patients who were already
experiencing substantial pain. First, it is possible that rilo-
nacept may have been more effective had it been adminis-
tered earlier relative to flare onset, since the ability of IL-1
inhibition to effect a reduction in pain by blocking the
cascade of downstream inflammatory mediators may
depend on the timing of treatment. Results of a clinical
trial with colchicine indicated the success of treating acute
gout flares within 12 hours of onset [12]. Secondly, after a
single SC injection, Tmax for rilonacept is approximately
48 to 72 hours. Since the primary endpoint was the change
from baseline to the average of the pain assessments at 24,
48 and 72 hours, it is possible that drug concentrations at
the gouty joint were insufficient during the majority of the




























*P < 0.001 and †P < 0.05 versus indomethacin monotherapy
Figure 4 Serum concentrations of high sensitivity C-reactive protein (hs-CRP) from baseline to day 31 (safety follow up).
SC, subcutaneous.
Table 2 Treatment-emergent adverse events through safety follow up (day 31): incidence ≥ 5% in any treatment
group
Number (%) of patients
Adverse event (AE) SC placebo + oral indomethacin
(n = 77)1
SC rilonacept + oral indomethacin
(n = 73)1
SC rilonacept + oral placebo
(n = 75)
Any AE 23 (29.9) 34 (46.6) 27 (36.0)
Discontinuations due to AE 2 (2.6) 1 (1.4) 1(1.3)
Serious AE 0 3 (4.1) 0
Headache 6 (7.8) 4 (5.5) 7 (9.3)
Dizziness 4 (5.2) 3 (4.1) 2 (2.7)
1Numbers differ from patient disposition since one patient was administered the wrong drug.
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size of rilonacept (approximately 250 kilodaltons) may
limit the rate of distribution from plasma to target tissues
involved in a gout attack. It is possible that, had rilonacept
been administered by the intravenous route, higher serum
concentrations achieved soon after administration could
have driven greater drug penetration to target tissues, and
hence, greater efficacy in treating acute gout flares.
These data appear to contrast with recent clinical trials
of another IL-1 inhibitor, canakinumab, which demon-
strated that IL-1 inhibition ameliorated inflammation
and pain during an ongoing gout flare as compared to
low-dose steroid injections [30,31]. Several reasons
should be noted that may account for this difference,
including that the canakinumab studies had several clini-
cally relevant differences in study design and study popu-
lations. For example, the canakinumab studies were
conducted in patients poorly responsive to, or unable to
tolerate, NSAID and/or colchicine therapy. The duration
of acute gout flare before therapy was allowed to be up to
5 days in each of the canakinumab studies [30,31] com-
pared with only 48 hours in the current study of rilona-
cept. Prior to enrollment, patients in the current study
were also specifically required to have tolerated NSAIDs
and to have demonstrated symptomatic relief of gout
flare pain with NSAIDs. The active comparator in the
canakinumab studies was a corticosteroid, triamcinolone
acetonide, administered as a single IM dose of 40 mg.
This dose is lower than the single 60 mg IM dose pre-
viously suggested as being effective in two small clinical
studies in acute gout [41,42], and although it was asso-
ciated with partial pain relief in acute gout [30,31], the
significance of the clinical effect is uncertain in the
absence of comparison with placebo, or standard of care
(colchicine or NSAIDs). It should also be noted that the
indomethacin comparator in the current study has both
potent analgesic as well as anti-inflammatory properties.
Given the collective distinctions in study designs, the
extent of the intrinsic differences that may have contrib-
uted to the differing outcomes between the soluble
decoy receptor rilonacept and the monoclonal antibody
canakinumab are unclear. Differences in efficacy among
agents in another class of anti-cytokine therapy, TNF-a
antagonists, have been demonstrated to be related to
such factors in arthritic diseases other than gout [43,44].
It remains to be addressed whether doses of rilonacept
higher than employed in this study, selection of a differ-
ent patient population, or a different comparator or
route of administration (intravenous or intra-articular),
might be more effective for treatment of acute gout
flares. Interestingly, despite the lack of incremental effi-
cacy with rilonacept for pain reduction compared with
indomethacin in an acute gout flare, it should be noted
that rilonacept, both as monotherapy as well as in com-
bination with indomethacin, did result in significantly
greater early reductions in hs-CRP than indomethacin
monotherapy (P < 0.05). These reductions likely reflect
IL-1 inhibition by rilonacept, and are consistent with
those reported for canakinumab in acute gout flares
[30].
Treatment with rilonacept in this clinical setting was
generally well-tolerated, with the frequency of withdrawals
due to AEs similar across treatment groups. Although the
combination therapy group had a higher incidence of ser-
ious AEs relative to both of the monotherapy groups,
these AEs were not considered related to rilonacept.
Conclusions
In conclusion, in contrast with previous studies that have
demonstrated efficacy of rilonacept for prevention of acute
gout flares in patients initiating ULT, addition of rilona-
cept to an indomethacin treatment regimen and use of
rilonacept alone provided neither significant additional
pain relief nor superior pain relief, compared with indo-
methacin alone over the 72-hour period after treatment
initiation in acute gouty arthritis.
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